This study from Deng et al provides some novel information about the role of TFH-like cells in chronic graft versus host disease (cGVHD), using a mouse model system. The major claims of the paper are showing that extra-follicular CD4 T cells are involved in cGVHD pathogenesis and that cGVHD can be blocked by inhibiting these cells via an ICOS blockade, or via genetic disruption of the transcription factors Bcl6 or Stat3 in T cells. These finding are important for the understanding of cGVHD and also help to clarify respective roles of germinal center-associated TFH cells and extra-follicular TFH-like cells. However, there are a number of problems in the manuscript that weaken these conclusions, and a number of other concerns.
The following issues should be addressed in a revision: 1) What is the relationship of TFH cells and extra-follicular TFH-like cells in this model? In every mouse experiment, there should be a direct quantitation of TFH cells (CXCR5+ CD62L-low, PSGL-1-low) and extra-follicular TFH-like cells (CXCR5-CD62L-low, PSGL-1-low). It also would be useful to compare the expression of PD-1 and ICOS on these two populations. 2) What is the cytokine profile of the extra-follicular TFH-like cells in the cGVHD system? Does the cytokine profile change over the course of the disease? 3) Are the extra-follicular TFH-like cells promoting pathology via helping B cells make auto-Ab or are they making inflammatory cytokines that drive disease independent of Ab? 4) The nomenclature used for the "no GVHD" groups are confusing in Figures 2, 6, 7. What are in the groups that say, for instance, "B-BCL-6+/+ -noGVHD"? What is the difference between the "B-BCL-6+/+-noGVHD" and "B-BCL-6-/--noGVHD" groups? 5) Figure 3C purports to show a difference in CXCR4 expression but both groups just have black boxes with no apparent differences. 6) Figure 7A is missing a label 7) When are spleens analyzed in Figure 7G ? 8) In figure 8 , the cytokine arrow between pre-TFH and B cells should be going from the pre-TFH to B cells, not other way as shown 9) It should be noted that deletion of Bcl6 and Stat3 with CD4-cre affects Tregs, and specifically inhibit TFR cell generation. 10) References should be given for the source of the Bcl6-flox mice and the Stat3-flox mice 11) In discussion "T-B boarder" is written twice. It should be "T-B border" Reviewer #3 (ICOS, cytokine signaling, Tfh) (Remarks to the Author):
T follicular helper (Tfh) cells have emerged as a distinct subset/lineage of CD4+ T cells that are primarily responsible for providing help to B cells during immune responses to TD Ag and mediating the differentiation of B cells into memory and plasma cells during GC reactions in secondary lymphoid tissues. The critical function of Tfh cells is evident from animal models and human diseases where Tfh cells are reduced/absent and humoral immunity is impaired, while on the other hand excessive numbers/production or function of Tfh cells has been associated with, and likely causes, autoimmune conditions such as SLE etc. however, there are other "types" of CD4 T cells that also provide help to B cells that are not strictly located within the B-cell follicles -these have been coined extrafollicular CD4+ T cells, and were first identified and characterized by Joe Craft in the setting of a murine model of autoimmunity. Since then, other groups have identified analogous cells in normal humoral immune responses, implicating these cells in the early stages of B-cell activation and differentiation (pregerminal center).
In this current study, the authors have used numerous models of graft vs host disease and detailed physiological, developmental, cellular and functional analyses to reveal a critical role for extrafollicular CD4 T cells in disease pathogenesis. Importantly (but perhaps predictably) the generation of pathogenic extrafollicular CD4 T cells could be reduced by blocking ICOS/ICOS-L interactions, as well as genetic ablation of Bcl-6 or STAT3 in CD4 T cells. Overall, this study sheds substantial light on etiology of chronic GVHD, at least in murine models -it will need to be determined whether these findings are directly relevant to human GVHD. This notwithstanding, the study is well and comprehensively performed, and contains some important novel findings. Several comments follow that should be used as a guide to improve the novelty, mechanisms and conclusions of the findings.
1. The finding relating to the effects of STAT3 deficiency on disease need to be extended. First, what was the level of expression of Bcl-6 in Stat3-deficient CD4 T cells (and extrafollicular CD4 T cells specifically)? Second, Stat3 deficiency did not overcome acute GVHD, but greatly improved chronic GVHD. This raises questions about the nature and quality of extrafollicular CD4 T cells during these distinct phases of disease progression. Are these cells less likely to be pathogenic in the early/acute phase of GVHD? Third, Stat3 deficiency not only reduced pathogenic extrafollicular CD4 T cells but also increased Tregs. However, these latter cells were only assessed by phenotype -not function. Were the Stat3-deficient Tregs superior to WT Tregs at suppressing T cell activation and function? Was the increase in Tregs protective ie did disease severity worsen if Tregs were depleted from mice harbouring Stat3-deficient CD4 T cells? 2. several of the Figures contain results from data for gene expression from RNA Seq. these data need to be confirmed by Western blot or FACS. Eg Fig 3C - for CXCR4, CXCR5 and CCR7; Fig 4A - Fig 7A, it is not indicated which panels correspond to which experimental mice. 3. for the expts for Fig 5D, it is possible that the reduced level of detected ICOS expressed by the labelled cells by FACS in the mice receiving the anti-ICOS mAb reflects masking by the blocking ICOS mAb that was still bound to the cells. this needs to be determined. Also for this data the treatment regime was extreme -blocking ICOS Ab injected every 2nd day for 45 days. Was this necessary? Was there a shorter time frame in which the ICOS/ICOS-L interaction could be blocked and a physiological effect still be detected?
The authors have clarified some issues.
Reviewer #2 (Remarks to the Author):
As I wrote previously, the major claims of the paper are showing that extra-follicular CD4 T cells are involved in cGVHD pathogenesis and that cGVHD can be blocked by inhibiting these cells via an ICOS blockade, or via genetic disruption of the transcription factors Bcl6 or Stat3 in T cells. These findings are important for the understanding of cGVHD and also help to clarify respective roles of germinal center-associated TFH cells and extra-follicular TFH-like cells.
The revised manuscript addresses my most pressing concerns, but I still find it disconcerting that the authors do not have flow cytometry comparing Tfh versus the supposed extra-follicular Tfh-like cells. However, the RNA expression data does address CXCR5 expression and basically addresses the issue.
The legends are better, but in Figure 1 , it should be laid out clearly what Group 1 is versus Group 2 versus Group 3. Also, TCD should be defined somewhere in the main manuscript.
In summary, the main conclusions of the paper are significant for the field, and convincingly presented. Statistics seem fine and there is probably enough detail given for reproduction by other researchers.
Reviewer #3 (Remarks to the Author):
The authors have adequately addressed most of the concerns raised in teh original review of their manuscript. However, they did not assess/confirm differential gene expression by FACS, as requested -rather they have confirmed these differences by qPCR. This should suffice -tho it would have been preferable to see either protein expression (ie FACS analyses) or simply for the authors to state that they felt the data presented as qPCR was suitable.
Deng et al. report on the influence of BCL6 and STAT3 deficiency in CD4 T cells on germinal center formation and occurrence of graft versus host disease. The manuscript is well written but has several shortcomings in particular with respect to novelty and methods. We regret that we have created a misunderstanding about the main focus of our manuscript.
We agree that it has been reported by Flynn and Blazar et al that there were enlarged germinal center in the lymphoid tissues of chronic GVHD recipients at the disease onset, and those publications are cited in the introduction and discussion (see pages 4 and 16). However, in our report, we have clearly demonstrated that there is no enlargement of germinal centers in the chronic GVHD recipients. Instead, lymphofollicles and germinal centers were destroyed in chronic GVHD recipients at the disease onset. This discrepancy is not due to model difference, because we have checked all chronic GVHD models reported by Flynn et al, and we have consistently found destruction of lymphofollicles and loss of germinal centers (see Supplemental Figures 4,5, 6 and 7). Furthermore, by using donor transplants with specific BCL6 deficiency in B cells that is not able to give rise to germinal centers, we have demonstrated that germinal center formation is dispensable for development of chronic GVHD (Fig 2).

We also agree that others have shown amelioration of acute and chronic GVHD by blockade of ICOS interaction with its ligand, and these publications have been incorporated into our text (see page 17). However, by using B-BCL6 deficient transplants that cannot give rise to germinal centers, we have specifically demonstrated that extrafollicular CD4 + T and B cell interactions also depend on ICOS/ICOS ligand interactions. Therefore, blockade ICOS/ICOS ligand interaction amelioration of chronic GVHD in the report by Flynn et al may not result from prevention of germinal center formation, because our studies showed that there was no germinal center formation in those models. Instead, prevention of chronic GVHD may result from blocking extrafollicular CD4 + T and B interaction. This point has been incorporated into discussion (see page 17). Taken collectively, the novelty of our report is very high, because it has clarified a highly controversial question about the role of germinal center formation in chronic GVHD pathogenesis. Our report has highlighted novel mechanisms for the pathogenesis of autoimmune-like chronic GVHD that are likely to be relevant to other autoimmune conditions.
2. Another weakness is the use of a well-known acute GVHD model (B6 into BALB/c) while the authors state that they investigate chronic GVHD. They considered the skin inflammation as a typical sign for chronic GVHD but acute GVHD is affecting the skin as well. Only in some initial experiment the authors have used a chronic GVHD model (LP/J to C57BL/6). A previous study by the same authors used the same model but named it acute GVHD model. The survival of the WT is very similar to the model that is described in the manuscript as cGVHD. We regret the misunderstanding about our chronic GVHD model. Fig. S23 and page14, first paragraph) .
We agree with the reviewer that the HCT model of C57BL/6 donor to BALB/c recipient has been traditionally considered as an acute GVHD model by us and by other investigators. However, in a previous report (Wu et al, J. Immunol 2013), we have demonstrated that after titrating down the numbers of C57BL/6 donor spleen cells or T cells in the graft, BALB/c recipients survived beyond the acute GVHD phase and emerged into a well characterized chronic GVHD phase. The recipients survived for more than 60 days after transplantation with grafts containing low numbers of donor spleen or T cells, and they developed clinical signs and histopathology that reflect manifestations of human chronic GVHD, including scleroderma, lymphocytic bronchitis, and damage in the salivary and lacrimal glands. In addition, we showed with other models that induction of chronic GVHD does not depend on the donor and recipient strain combination, but it does dependent on survival time after HCT. This new concept about induction of chronic GVHD in murine models has been recognized by many investigators and has been cited by a lot of publications including a recent review (Socié
3. Figure 6 : Splenocytes from either WT or B-BCL-6 -/-C57BL/6 donors are used -therefore the authors cannot distinguish between effects caused by the BCL-6 deficient T cells or B-cells or other splenic immune cells of donor origin.
We regret the misunderstanding here. We would like to clarify that comparison of WT and specific BCL6 deficiency in B cells (B-BCL6
-/-) is with Figure 2 . In Figure 6, 
germinal centers in chronic GVHD recipients, as compared to control no-GVHD recipients given TCD-BM cells only. We observed much smaller germinal centers in recipients with very mild chronic GVHD. What's more chronic GVHD was successfully induced in recipiens which lack of germinal center formation (Figure 2)Therefore, our data indisputablely showed that chronic GVHD is associated with destruction or loss of germinal centers and was not associated with enlarged germinal centers (see result section page 6-7 and discuss section page 16).
We agree that mild or non-lethal acute GVHD is likely to damage the lymphoid structure and prevent germinal center formation in chronic GVHD recipients (see discussion section page17, first paragraph).
5. The adequate control for expansion of PSGL-1 lo CD4 + cells would be a syngeneic transplantation. The additional transplantation of 1x10 6 splenocytes in GVHD recipients in comparison to no-GVHD recipients raises the question if the increased number that was observed is just by homeostatic proliferation and survival of these cells or by alloantigen based activation. Syngeneic transplantation of 1x10 6 splenocytes would also account for the additional transplanted T cell numbers and the homeostatic proliferation. Figure S14 and the Results on page 10, second paragraph).
We found that there was no expansion of PSGL-1 lo
CD4 + T cells in syngeneic transplantation recipients (see newly added data
6. The microarray data are not very convincing with n=2. They have to be confirmed by quantitative RT-PCR using independent samples and on the protein level. Figures1, 4, 6, 7 and pages31, 34, 36, 37) .
Statistical analysis for GVHD score, bodyweight and survival have been added and indicated in corresponding figure legends (see
Minor comments: …pathogenic CD4+ T and B cells, but the role of extrafollicular… Chronic GVHD often follows acute GVHD. Stimmt das?
Yes, it is true based on our best knowledge.
…cGVHD recipients… cGVHD patients
We did not understand the question and cannot address this point.
Introduction to much/complicated/detailed.
We intend to prepare sufficient background information for broad readership to help their understanding of this report, since Nature Communications has broader readership as compared to Blood.
BALB/c recipients were injected with TCD-BM plus 1x10 6 or 0.01 x10 6 C57BL/6 spleen cells.
Yes, it is true!
Reviewer #2 (Tfh, Bcl6) (Remarks to the Author):
The following issues should be addressed in a revision: 1) What is the relationship of TFH cells and extra-follicular TFH-like cells in this model? In every mouse experiment, there should be a direct quantitation of TFH cells (CXCR5+ CD62L-low, PSGL-1-low) and extrafollicular TFH-like cells (CXCR5-CD62L-low, PSGL-1-low). It also would be useful to compare the expression of PD-1 and ICOS on these two populations. (Fig. 9) 
We greatly appreciate the very insightful comment. The relationship of TFH and extra-follicular TFH-like cells in chronic GVHD mice remains unclear, although we have uncovered some hints. Further studies in the future are required. As depicted in summary diagram
T cells restored cutaneous chronic GVHD (see Supplemental figure S17 on page 13 in result section).
2) What is the cytokine profile of the extra-follicular TFH-like cells in the cGVHD system? Does the cytokine profile change over the course of the disease?
We used intracellular cytokine flow cytometry and found that PSGL-1 lo CD4 + T cells in the spleen of chronic GVHD mice at 21 days after HCT produced Figure 3D and (Fig. 4 and 5 4) The nomenclature used for the "no GVHD" groups are confusing in Figures 2, 6 , 7. What are in the groups that say, for instance, "B-BCL-6 +/+ -no GVHD"? What is the difference between the "B-BCL-6 +/+ -no GVHD" and "B-BCL-6 -/--no GVHD" groups?
To avoid confusion, we have clarified the labels in corresponding figure legends. Figure 3C purports to show a difference in CXCR4 expression but both groups just have black boxes with no apparent differences.
5)
We agree that the color difference in Figure 3C for CXCR4 was not clear. We have use real-time PCR to compare the difference and found it was statistically significant (see newly added Fig S12) 6) Figure 7A is missing a label
The label has been added.
7)
When are spleens analyzed in Figure 7G ?
60 days after HCT. This information has been added to the figure legend. figure 8 , the cytokine arrow between pre-TFH and B cells should be going from the pre-TFH to B cells, not other way as shown.
8) In
This error has been fixed.
9) It should be noted that deletion of Bcl6 and Stat3 with CD4-cre affects Tregs, and specifically inhibit TFR cell generation. et al: Nature medicine 17, 983-988 (2011); We et al: PloS one 11, e0155040 (2016) T follicular helper (Tfh) cells have emerged as a distinct subset/lineage of CD4+ T cells that are primarily responsible for providing help to B cells during immune responses to TD Ag and mediating the differentiation of B cells into memory and plasma cells during GC reactions in secondary lymphoid tissues. The critical function of Tfh cells is evident from animal models and human diseases where Tfh cells are reduced/absent and humoral immunity is impaired, while on the other hand excessive numbers/production or function of Tfh cells has been associated with, and likely causes, autoimmune conditions such as SLE etc. however, there are other "types" of CD4 T cells that also provide help to B cells that are not strictly located within the B-cell folliclesthese have been coined extrafollicular CD4+ T cells, and were first identified and characterized by Joe Craft in the setting of a murine model of autoimmunity. Since then, other groups have identified analogous cells in normal humoral immune responses, implicating these cells in the early stages of B-cell activation and differentiation (pre-germinal center).
We agree that deletion of BCL6 and Stat3 in CD4 + T cells decreases the number of follicular Treg cells (Chung
1. The finding relating to the effects of STAT3 deficiency on disease need to be extended. First, what was the level of expression of Bcl-6 in Stat3-deficient CD4 T cells (and extrafollicular CD4 T cells specifically)? Second, Stat3 deficiency did not overcome acute GVHD, but greatly improved chronic GVHD. This raises questions about the nature and quality of extrafollicular CD4 T cells during these distinct phases of disease progression. Are these cells less likely to be pathogenic in the early/acute phase of GVHD? Third, Stat3 deficiency not only reduced pathogenic extrafollicular CD4 T cells but also increased Tregs. However, these latter cells were only assessed by phenotype -not function. Were the Stat3-deficient Tregs superior to WT Tregs at suppressing T cell activation and function? Was the increase in Tregs protective ie did disease severity worsen if Tregs were depleted from mice harbouring Stat3-deficient CD4 T cells? Fig. S19 and Fig. S24 
